This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Uckun, F. M. Articles by Levine, A. Search for Related Content PubMed PubMed Citation Articles by Uckun, F. M. Articles by Levine, A.

Treatment of Therapy-Refractory B-Lineage Acute Lymphoblastic Leukemia with an Apoptosis-inducing CD19-directed Tyrosine Kinase Inhibitor¹

The Parker Hughes Cancer Center, Hughes Institute, St. Paul, Minnesota 55113 [F. M. U., C-L. C., K. O., D. E. M.]; Biotherapy Program, University of Minnesota Academic Health Center, Minneapolis, Minnesota 55455 [Y. M.]; Kenneth Norris Cancer Center, University of Southern California, Los Angeles, California 90033 [A. L.]; University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242 [F. G.]; Cedar Sinai Medical Center, Los Angeles, California 90048 [C. H.]; and University of Wisconsin, Milwaukee, Wisconsin 53226 [J. T. C.]

Seven children and eight adults with CD19⁺ B-lineage acute lymphoblastic leukemia, as well as one adult with chronic lymphocytic leukemia, were treated with the CD19 receptor-directed tyrosine kinase inhibitor B43-Genistein. All patients had failed previous chemotherapy regimens, and six patients had relapsed after bone marrow transplantation. B43-Genistein was administered as a 1-hour i.v. infusion at 0.1–0.32 mg/kg/day dose levels for 10 consecutive days or 3 consecutive days weekly for a total of nine doses. B43-Genistein was well tolerated by all patients with no life-threatening side effects. There were six episodes of grade 2–3 fever, two of which were clearly drug related, one episode each of grade 3 myalgia, grade 2 sinus tachycardia, and grade 2 vascular leak syndrome. There was one durable complete remission and two transient responses. Pharmacokinetic analyses in 12 patients revealed a plasma half-life of 20 ± 5 h, mean residence time of 24 ± 5 h, and a systemic clearance rate of 20 ± 3 ml/h/kg. Moderate levels of human antimouse antibody (HAMA) ranging from 20–87 ng/ml were detected in the day 28 blood samples from three of nine cases examined. Treatment of these three HAMA-positive patients with a second course of B43-Genistein did not yield measurable immunoconjugate levels in the plasma, indicating that the administered B43-Genistein molecules were rapidly cleared from circulation due to the HAMA. On the basis of its acceptable toxicity profile and its ability to elicit objective responses at nontoxic dose levels, B43-Genistein may provide the basis for an effective treatment strategy for B-lineage acute lymphoblastic leukemia patients who have failed standard therapy.

This article has been cited by other articles:

				J. Zalevsky, I. W. L. Leung, S. Karki, S. Y. Chu, E. A. Zhukovsky, J. R. Desjarlais, D. F. Carmichael, and C. E. Lawrence The impact of Fc engineering on an anti-CD19 antibody: increased Fc{gamma} receptor affinity enhances B-cell clearing in nonhuman primates Blood, April 16, 2009; 113(16): 3735 - 3743. [Abstract] [Full Text] [PDF]

				C. A. Huff, W. Matsui, B. D. Smith, and R. J. Jones The paradox of response and survival in cancer therapeutics Blood, January 15, 2006; 107(2): 431 - 434. [Abstract] [Full Text] [PDF]

				A. J. Marks, M. S. Cooper, R. J. Anderson, K. H. Orchard, G. Hale, J. M. North, K. Ganeshaguru, A. J. Steele, A. B. Mehta, M. W. Lowdell, et al. Selective Apoptotic Killing of Malignant Hemopoietic Cells by Antibody-Targeted Delivery of an Amphipathic Peptide Cancer Res., March 15, 2005; 65(6): 2373 - 2377. [Abstract] [Full Text] [PDF]

				R. J. Jones, W. H. Matsui, and B. D. Smith Cancer Stem Cells: Are We Missing the Target? J Natl Cancer Inst, April 21, 2004; 96(8): 583 - 585. [Full Text] [PDF]

				P. Mitchell, F.-T. Lee, C. Hall, A. Rigopoulos, F. E. Smyth, A.-M. Hekman, G. M. van Schijndel, R. Powles, M. W. Brechbiel, and A. M. Scott Targeting Primary Human Ph+ B-Cell Precursor Leukemia-Engrafted SCID Mice Using Radiolabeled Anti-CD19 Monoclonal Antibodies J. Nucl. Med., July 1, 2003; 44(7): 1105 - 1112. [Abstract] [Full Text] [PDF]

				Z.-y. Wang Ham-Wasserman Lecture: Treatment of Acute Leukemia by Inducing Differentiation and Apoptosis Hematology, January 1, 2003; 2003(1): 1 - 13. [Abstract] [Full Text] [PDF]

				F. TOSETTI, N. FERRARI, S. DE FLORA, and A. ALBINI Angioprevention': angiogenesis is a common and key target for cancer chemopreventive agents FASEB J, January 1, 2002; 16(1): 2 - 14. [Abstract] [Full Text] [PDF]